These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7562063)

  • 1. Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle.
    Sgouros G
    J Nucl Med; 1995 Oct; 36(10):1910-2. PubMed ID: 7562063
    [No Abstract]   [Full Text] [Related]  

  • 2. Validation of an analytical expression for the absorbed dose from a spherical beta source geometry and its application to micrometastatic radionuclide therapy.
    Sarfaraz M; Wessels BW
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3020s-3023s. PubMed ID: 10541338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How far have we come with solid (nonhematologic) tumor radioimmunotherapy?
    Breitz HB
    J Nucl Med; 2000 Dec; 41(12):2011-4. PubMed ID: 11138686
    [No Abstract]   [Full Text] [Related]  

  • 4. [Alpha-radioimmunotherapy: a review of recent developments].
    Supiot S; Thillays F; Rio E; Mahé MA; Barbet FJ; Kraeber-Bodéré F; Chérel M
    Cancer Radiother; 2007 Sep; 11(5):252-9. PubMed ID: 17604673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Radioimmunotherapy in the treatment of cancers].
    Mahé M; Chatal JF
    Bull Cancer; 1994 Sep; 81(9):788-99. PubMed ID: 7703569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling of tumor uptake to determine the time-dose-fractionation effect in radioimmunotherapy.
    Liu A; Williams LE; Demidecki AJ; Raubitschek AA; Wong JY
    J Nucl Med; 1994 Sep; 35(9):1561-4. PubMed ID: 8071711
    [No Abstract]   [Full Text] [Related]  

  • 7. Determination of biological vector characteristics and nanoparticle dimensions for radioimmunotherapy with radioactive nanoparticles.
    Nuttens VE; Wéra AC; Bouchat V; Lucas S
    Appl Radiat Isot; 2008 Feb; 66(2):168-72. PubMed ID: 17913502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant and combined radioimmunotherapy: problems and prospects on the road to Minerva.
    Goldenberg DM
    J Nucl Med; 2006 Nov; 47(11):1746-8. PubMed ID: 17079805
    [No Abstract]   [Full Text] [Related]  

  • 9. Beta radiation.
    Welsh JS
    Oncologist; 2006 Feb; 11(2):181-3. PubMed ID: 16476838
    [No Abstract]   [Full Text] [Related]  

  • 10. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
    Juweid ME; Zhang CH; Blumenthal RD; Hajjar G; Sharkey RM; Goldenberg DM
    J Nucl Med; 1999 Oct; 40(10):1609-16. PubMed ID: 10520699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy of cancer with radiolabeled antibodies.
    Goldenberg DM
    J Nucl Med; 2002 May; 43(5):693-713. PubMed ID: 11994535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunotherapy of micrometastases: a continuing evolution.
    Zanzonico P
    J Nucl Med; 1992 Dec; 33(12):2180-3. PubMed ID: 1460512
    [No Abstract]   [Full Text] [Related]  

  • 13. Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung.
    Shen S; DeNardo GL; Yuan A; DeNardo DA; DeNardo SJ
    J Nucl Med; 1994 Aug; 35(8):1381-9. PubMed ID: 8046498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor control probability for tumor therapy with beta radionuclide interstitial injection.
    Chen Y; Geng J; Tian J; He Y; Chen S
    Biomed Mater Eng; 2004; 14(3):333-5. PubMed ID: 15299245
    [No Abstract]   [Full Text] [Related]  

  • 15. Fractionated radioimmunotherapy using low doses of iodine-131 labeled anti-CEA monoclonal antibody after tumor volume reduction.
    Tian J; Ding Y; Zhang J; Cao L; Yin D
    Chin Med J (Engl); 2000 Jan; 113(1):53-8. PubMed ID: 11775212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of radioimmunotherapy in a mouse model of testicular tumor with micrometastases defined by polymerase chain reaction.
    Koshida K; Yokoyama K; Endo Y; Kadono Y; Hirano K; Sasaki T; Mizokami A; Namiki M
    Oncol Rep; 2002; 9(6):1261-6. PubMed ID: 12375031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta dose-rate distributions in microscopic spherical tumors for intraperitoneal radioimmunotherapy.
    Syme A; McQuarrie S; Fallone BG
    Int J Radiat Oncol Biol Phys; 2003 Aug; 56(5):1495-506. PubMed ID: 12873695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-fire doses from beta-emitting radionuclides in targeted radiotherapy. A theoretical study based on experimentally measured tumor characteristics.
    Enger SA; Hartman T; Carlsson J; Lundqvist H
    Phys Med Biol; 2008 Apr; 53(7):1909-20. PubMed ID: 18364546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted radionuclide therapy for solid tumors: an overview.
    DeNardo SJ; Denardo GL
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S89-95. PubMed ID: 16979448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Systemic radiotherapy using monoclonal antibodies. Options and problems].
    Sautter-Bihl ML; Wannenmacher M; Bihl H
    Strahlenther Onkol; 1993 Jun; 169(6):358-65. PubMed ID: 8316939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.